Related Experiment Video
Updated: May 8, 2026

Detecting the Lyme Disease Spirochete, Borrelia Burgdorferi, in Ticks Using Nested PCR
Published on: February 4, 2018
Erdheim-Chester Disease: a comprehensive review of the literature
Roei D Mazor1, Mirra Manevich-Mazor, Yehuda Shoenfeld
1The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel. shoenfel@post.tau.ac.il.
Insights
Erdheim-Chester Disease (ECD) is a rare histiocytosis affecting adults, presenting with bone pain and multi-system involvement. Diagnosis requires biopsy, and treatment options like interferon-alfa are limited, with a 5-year survival rate of 68%.
Area of Science:
- Rare diseases
- Histiocytosis
- Immunology
Background:
- Erdheim-Chester Disease (ECD) is a rare non-Langerhans cell histiocytosis primarily affecting adults aged 50-70.
- It is a multi-systemic disorder with significant morbidity due to histiocytic infiltration of vital organs.
- Commonly affected sites include the skeleton, CNS, cardiovascular system, lungs, kidneys, and skin.
Purpose of the Study:
- To provide a comprehensive overview of Erdheim-Chester Disease.
- To consolidate current knowledge on clinical, radiological, and pathological manifestations.
- To discuss diagnostic challenges, differential diagnoses, and therapeutic strategies.
Main Methods:
- Literature review and synthesis of existing data on Erdheim-Chester Disease.
- Analysis of clinical presentations, diagnostic criteria, and treatment outcomes.
- Consolidation of scientific understanding regarding ECD etiology and pathogenesis.
Main Results:
- ECD most commonly presents with bone pain and affects multiple organ systems.
- Diagnosis is confirmed by identifying CD68(+), CD1a(-) histiocytes in biopsy specimens.
- Bilateral symmetric bone scintigraphy findings are suggestive of ECD.
- The V600E BRAF mutation is found in about half of patients.
Conclusions:
- ECD presents diagnostic and therapeutic challenges due to its rarity.
- Interferon-alfa is the first-line treatment, with cladribine, anakinra, and vemurafenib as potential second-line options.
- The 5-year survival rate for ECD is currently 68%.
Abstract:
Erdheim-Chester Disease (ECD) is a rare form of non Langerhans' cell histiocytosis. Individuals affected by this disease are typically adults between their 5th and 7th decades of life. Males and females are almost equally affected. The multi systemic form of ECD is associated with significant morbidity, which may arise due to histiocytic infiltration of critical organ systems. Among the more common sites of involvement are the skeleton, central nervous system, cardiovascular system, lungs, kidneys (retroperitoneum) and skin. The most common presenting symptom of ECD is bone pain. The etiology of ECD is unknown yet thought to be associated with an intense TH1 immune response. It may also be associated with the V600E BRAF mutation, as described in as many as half of the patients in recent studies. Bilateral symmetric increased tracer uptake on 99mTc bone scintigraphy affecting the periarticular regions of the long bones is highly suggestive of ECD. However, definite diagnosis of ECD is established only once CD68(+), CD1a(-) histiocytes are identified within a biopsy specimen. At present, this obscure ailment embodies numerous challenges to medical science. Given its rarity, it is diagnostically elusive and requires a high level of clinical suspicion. Therapeutically, it is of limited alternatives. Currently, interferon-α is the most extensively studied agent in the treatment of ECD and serves as the first line of treatment. Treatment with other agents is based on anecdotal case reports and on the basis of biological rationale. Nevertheless, cladribine (2CDA), anakinra and vemurafenib are currently advocated as promising second line treatments for patients whose response to interferon-α is unsatisfactory. Overall, the 5 year survival of ECD is 68%. Herein, the authors mustered and brought about a panoramic consolidation of all the relevant facts regarding ECD. This work highlights the different clinical, radiological and pathological manifestations associated with ECD, the differential diagnoses, the various treatment options and the acknowledged science explaining the disease.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis II: Clinical Features of Infective Endocarditis
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
